Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment

NCT05793450 · Completed

Last updated 2026-05-28

This clinical trial is testing how the body processes the drug IBI362 in people with and without kidney problems.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) study

Participants 20 people

Who can join Ages 18–75 · all sexes Healthy volunteers accepted.

Timeline Started 2023-05 · est. completion 2023-11

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT05793450 ↗

Description as written by the study sponsor.

The purpose of this study is to assess how fast IBI362 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.

Treatments tested

IBI362 Drug

2.0mg, SC, single dose

Main thing measured	Pharmacokinetics (PK): Maximum Concentration (Cmax) of IBI362
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions studied	Renal Impairment
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05793450 ↗